Comparative Study: Vaginal Promestriene Use, Fractional CO2 LASER and Radiofrequency in the Vaginal Atrophy Treatment
NCT ID: NCT04717245
Last Updated: 2021-01-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
75 participants
INTERVENTIONAL
2018-10-25
2020-02-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study was carried out at the outpatient clinic of Lower Genital Tract ambulatory of the Discipline of Gynecology, Department of Obstetrics and Gynecology, Clinical Hospital, Faculty of Medicine, University of São Paulo, involving 75 women who were divided after randomization in three groups:
Group 1 - treatment with topical vaginal promestriene (n = 25 patients); Group 2 - treatment with fractional CO2 LASER (n = 25 patients); Group 3 - fractional microablative radiofrequency treatment (n = 25 patients).
An evaluation of the complaints were be performed through questionnaires on sexuality, quality of life and urinary incontinence, as well as biopsies of the vaginal wall for histomorphometric, immunohistochemical and molecular biology study before and after six months of treatment. The duration of the study were fifteen months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Fractional CO2 Laser Treatment Efficacy and Comparison to Vaginal Estrogen Therapy in Postmenopausal Women With Vulvovaginal Atrophy
NCT02419729
Evaluating the Efficacy of Temperature-controlled Radiofrequency (TRF) in the Treatment of Vulvovaginal Atrophy.
NCT04657536
Efficacy of Fractional CO2 Laser Treatment in Post-Menopausal Women With Vaginal Atrophy
NCT06726746
LASER and Radiofrequency and Genitourinary Syndrome of Menopause
NCT04045379
Use of Fractional CO2 Laser for the Treatment of Vulvovaginal Atrophy: a Double-blinded Randomized Placebo-controlled Clinical Trial.
NCT04021966
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Division of groups:
Were included in the study 75 patients, divided into three groups:
Group 1 - Treatment with topical vaginal promestriene - 25 patients in this group were included patients free of systemic or topical hormonal treatment for at 3 months
Group 2 - Treatment with CO2 LASER - 25 patients, in this group were included patients free of systemic or topical hormonal treatment for at 3 months.
Group 3 - Treatment with microablative fractionated radiofrequency - 25 patients in this group were included patients free of systemic or topical hormonal treatment for at least 3 months.
The present study was open and randomized. The randomization was be performed through the software "Test Generator Software Standard Edition"
At the first visit, all patients responded to the clinical questionnaire of female sex quotient (QS-F), the quality of life questionnaire (SF-36) and the urinary incontinence questionnaire.
All patients were submitted to specular gynecological examination to collect cervical-vaginal cytology, biopsy of 1/3 proximal vaginal wall for histological analysis and immunohistochemistry.
After the results of the examinations and possible treatments required, the patients were referred for the proposed treatments according to their randomized group.
Sampling Cytology :Cervical and vaginal oncology cytology were collected through a smear on a slide with fixative.
The histological expression of the following immunohistochemical parameters will be evaluated:
* Presence and density of estrogen receptors
* Vascular density
* Thickness of the epithelium
* Density of collagen fibers
* Vaginal microbiota
* Vaginal pH
In this study, it will be done a Morphological Analysis, a Histomorphometric analysis and e Immunohistochemical analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
Group 1 - Treatment with topical vaginal promestriene - 25 patients were included in this group
Group 2 - Treatment with fractional CO2 LASER - 25 patients were included in this group
Group 3 - Treatment with microablative fractional radiofrequency - 25 patients were included in this group
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fractional CO2 LASER
Vaginal fractional CO2 LASER 3 sessions applications
Fractional CO2 LASER
LASER treatment with fractional CO2 Laser was performed in 3 sessions with intervals of 4 weeks between them. Before each session, the patients underwent specular examination.
Fractional CO2 LASER was applied following these parameters, fixed in all sessions: vagina wall - power40 W, dwel time 1000 mcs, spacing 1000 mcm and stack 2, vestibule - power 10W, dwel time 500mcs, spacing 300mcg and satck 1
Microablative fractional radiofrequency
Vaginal Microablative fractional radiofrequency 3 sessions application
Microablative Fractional radiofrequency
Microablative fractional radiofrequency was performed with the equipment calibrated in FRAXX mode, 45W, Low Energy program 40 milliseconds in the vaginal and introitus wall. Lidocaine spray was applied to vaginal introitus before the procedure.
The patient was in the gynecological position. The vaginal speculum was placed and, afterwards, the vaginal antisepsis was performed with aqueous chlorhexidine and cleaning with 0.9% saline solution.
All liquid contents were wiped off before beginning the procedure. The fractured tip will be pressed lightly and as perpendicular as possible into the vulvar or vaginal surface, ensuring full contact of all points in the tissue, starting at the lateral vaginal walls and from the proximal to the distal third.
Promestriene Vaginal
Promestriene vaginal use during 3 months
Promestriene Vaginal
Patients used promestriene vaginal cream for 3 months. The use was recommended to be diary fot the first 2 weeks, and then, repeat every 3 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Promestriene Vaginal
Patients used promestriene vaginal cream for 3 months. The use was recommended to be diary fot the first 2 weeks, and then, repeat every 3 days.
Fractional CO2 LASER
LASER treatment with fractional CO2 Laser was performed in 3 sessions with intervals of 4 weeks between them. Before each session, the patients underwent specular examination.
Fractional CO2 LASER was applied following these parameters, fixed in all sessions: vagina wall - power40 W, dwel time 1000 mcs, spacing 1000 mcm and stack 2, vestibule - power 10W, dwel time 500mcs, spacing 300mcg and satck 1
Microablative Fractional radiofrequency
Microablative fractional radiofrequency was performed with the equipment calibrated in FRAXX mode, 45W, Low Energy program 40 milliseconds in the vaginal and introitus wall. Lidocaine spray was applied to vaginal introitus before the procedure.
The patient was in the gynecological position. The vaginal speculum was placed and, afterwards, the vaginal antisepsis was performed with aqueous chlorhexidine and cleaning with 0.9% saline solution.
All liquid contents were wiped off before beginning the procedure. The fractured tip will be pressed lightly and as perpendicular as possible into the vulvar or vaginal surface, ensuring full contact of all points in the tissue, starting at the lateral vaginal walls and from the proximal to the distal third.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical menopause - last menstrual period from 1 to 5 years from the date of recruitment
* FSH measurement\> 25 IU / ml, estrogen \<20 æg / ml
* Patients with vaginal atrophy and clinical and / or sexual symptoms
* Patients without hormonal treatment for at least five years
Exclusion Criteria
* Altered oncology cytology of the cervix and / or vagina
* Vaginal infections
* Connective tissue diseases
* Immunosuppression
* Coagulation change
* Diabetes Mellitus
* Thyroid diseases
* Use of systemic or local feminine hormones
* Use of other substances with estrogenic properties
40 Years
65 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Sao Paulo General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jose Maria Soares Junior, PHD
Role: STUDY_DIRECTOR
Universidade de São Paulo departamento de ginecologia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Disciplina de ginecologia - departamento de ginecologia e obstetrícia - faculdade de medicina da USP
São Paulo, , Brazil
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Seganfredo IB, Bianchi C, Tacla M, Chedraui P, Haddad JM, Simoes R, Baracat EC, Soares JM Jr. Comparison of promestriene with vaginal fractional CO2 laser and radiofrequency treatments of genitourinary syndrome of menopause. Maturitas. 2024 Aug;186:108008. doi: 10.1016/j.maturitas.2024.108008. Epub 2024 Apr 24.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CAI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.